Background: Thyroid function depends on the essential trace mineral selenium, which is at the active center of the iodothyronine deiodinase enzymes that catalyze the conversion of the prohormone thyroxine (T 4 ) to the active form of thyroid hormone, triiodothyronine (T 3 ). Objective: Because selenium intake in the United Kingdom has fallen during the past 25 y, we wanted to determine whether current selenium status might be limiting conversion of T 4 to T 3 in the elderly, in whom marginal hypothyroidism is relatively common. Design: We investigated the effect of selenium supplementation in a double-blind, placebo-controlled trial in 501 elderly UK volunteers. Similar numbers of men and women from each of 3 age groups, 60 -64 y, 65-69 y, and 70 -74 y, were randomly allocated to receive 100, 200, or 300 g Se/d as high-selenium yeast or placebo yeast for 6 mo. As part of the study, plasma selenium, thyroid-stimulating hormone, and total and free T 3 and T 4 were measured. Data from 368 euthyroid volunteers who provided blood samples at baseline and 6 mo were analyzed. Results: Although selenium status at baseline correlated weakly with free T 4 (r ҃ Ҁ0.19, P 0.001) and with the ratio of free T 3 to free T 4 (r ҃ 0.12, P ҃ 0.02), we found no evidence of any effect of selenium supplementation on thyroid function, despite significant increases in plasma selenium. However, baseline plasma selenium in our study (x : 91 g/L) was somewhat higher than in previous supplementation studies in which apparently beneficial effects were seen. Conclusion: We found no indication for increasing selenium intake to benefit T 4 to T 3 conversion in the elderly UK population. Am J Clin Nutr 2008;87:370 -8.
INTRODUCTION
Thyroid hormones control, directly or indirectly, many processes crucial to growth, development, and metabolism. Development of thyroid insufficiency in adulthood is associated, among other symptoms, with decreased basal metabolic rate, poor resistance to cold, weight gain, fatigue, muscle weakness, lethargy, malaise, hypercholesterolemia, and adverse mental states such as impaired cognition and depression (1) (2) (3) . The elderly are at increased risk of thyroid insufficiency. By 55-64 y of age, as many as 13% of women and 6% of men will have an underactive thyroid, as defined by a plasma thyroid-stimulating hormone (TSH) concentration above the normal range, whereas the percentages rise to 21 and 16, respectively, in those aged ͧ 74 y (4). Serum 3,3',5-triiodothyronine (T 3 ) concentrations in the elderly are often low, largely attributable to nonthyroidal illness rather than age itself, although both result in decreased conversion of thyroxine (T 4 ) to T 3 (5, 6) . T 3 concentrations in healthy centenarians are Ȃ30% lower than those of healthy subjects aged 20 -64 y (7) . Even subclinical hypothyroidism, defined as normal T 4 and T 3 with elevated TSH, may be associated with some thyroid insufficiency symptoms and is present in 4 -8.5% of the general population; it may be as high as 20% in women 60 y (8) .
It is now recognized that adequate supplies of both iodine and the essential trace element selenium are required for optimal thyroid function. Incorporated into the amino acid selenocysteine, selenium is at the active center of a number of selenoenzymes required for thyroid function (9) . The selenoenzymes, glutathione peroxidase and thioredoxin reductase, are crucial to the protection of the thyroid from the hydrogen peroxide that is produced there to oxidize iodide for thyroid hormone synthesis (9, 10) . This is consistent with the inverse association found between selenium status and thyroid volume, thyroid tissue damage, and goiter in French women (11) and with the positive association between the incidence of thyroid cancer and low prediagnostic serum selenium concentration in Norway (12, 13) . Furthermore, the protective effects of selenium on the thyroid are confirmed by the finding that supplementation with 200 g/d of sodium selenite or selenomethionine decreased inflammation and thyroid autoantibody concentrations in patients with autoimmune thyroiditis (14 -16) , although, interestingly, a dose of 100 g selenomethionine/d was ineffective (16) .
In addition to this protective function, 3 selenoenzymes, the iodothyronine deiodinases, are required for the interconversion of the active and inactive forms of the thyroid hormones (9) . Type 1 and type 2 deiodinases are required for the systemic and local synthesis of biologically active T 3 from T 4 , whereas type 3 deiodinase catalyzes the conversion of T 4 to biologically inactive reverse T 3 and catabolizes T 3 to produce inactive 3,3Ј-diiodothyronine (9, 10) . The combination of these enzymes allows the precise regulation of thyroid hormone metabolism in specific tissues. Some evidence of the relevance of adequate selenium status to thyroid function was found in a Czech population of low selenium status (mean serum selenium: 49 g/L) wherein thyroid hormone concentrations were correlated with serum and urinary selenium (17) . Clearly then, there are a number of reasons why low or marginal selenium availability may cause problems with thyroid metabolism.
Although current iodine intake in the United Kingdom is believed to be sufficient for thyroid hormone metabolism (18), it is not clear that this is true for selenium. In light of the above information, it is of concern that intakes of selenium in the United Kingdom have fallen in recent years and now stand at around half government-recommended amounts (19) . Although the UK Reference Nutrient Intake is 75 and 60 g Se/d for men and women, respectively, current UK intakes average from 29 to 39 g Se/d (20, 21) . Although deiodinase activity is believed to be relatively well protected in conditions of marginal selenium availability (22) , there are some indications that, nonetheless, marginally deficient selenium intake may be compromising thyroid hormone metabolism in some locations. For example, in Scottish subjects supplemented with 50 g Se/d as sodium selenite or selenomethionine for 28 d, although no change was observed in plasma concentrations of TSH, total T 3 , total T 4 , free T 3 , or free T 4 , a significant correlation was found between the plasma total T 3 -to-T 4 ratio (T 3 :T 4 ) and plasma selenium concentration, consistent with incomplete conversion to T 3 at the baseline concentration (x : 79.7 g/L) of plasma selenium (23) .
A further factor relevant to an elderly population is that selenium status tends to decline in persons 60 -65 y of age (24, 25) . Thus, selenium supplementation (100 g sodium selenite/d) in a group of 36 elderly Italian subjects (mean baseline plasma selenium: 64 g/L) significantly decreased plasma total T 4 concentrations, consistent with increased deiodinase activity, although there was no change in serum concentrations of TSH, total T 3 , or free T 4 (6) .
In light of the above reports, we hypothesized that the current selenium intake in the United Kingdom might be limiting the conversion of T 4 to T 3 in the elderly. We therefore investigated the effect of selenium on thyroid function in a study ancillary to the UK PRECISE (PREvention of Cancer by Intervention with SElenium) pilot study (26) . In this double-blind, placebocontrolled trial, 501 UK volunteers aged 60 -74 y were randomly allocated to receive 100, 200, or 300 g Se/d as high-selenium yeast or a placebo yeast. Of these volunteers, 368 were euthyroid and provided blood samples at baseline and at 6 mo that were used for evaluation of thyroid function and selenium status.
SUBJECTS AND METHODS
The UK pilot study for the planned international PRECISE (Prevention of Cancer by Intervention with Selenium) trial was set up to assess the viability of conducting the main trial in the United Kingdom. It was performed in 4 general practices of the Medical Research Council General Practice Research Framework in the United Kingdom with differing demographic characteristics: Guisborough and Linthorpe (North East), Bromsgrove (West Midlands), and Bungay (East Anglia). No formal power calculations were performed for the pilot study, and the target accrual (510 subjects in 12 mo) was chosen to give sufficient subjects from which to be able to draw reasonable inferences about recruitment, compliance, and loss to follow-up, while keeping costs within reasonable bounds. Assessment of thyroid function was a planned subsidiary analysis on blood samples stored for research within the trial.
Subjects and recruitment
Between June 2000 and July 2001, research nurses recruited similar numbers of male and female volunteers from each of 3 age groups: 60 -64 y, 65-69 y, and 70 -74 y. Exclusion criteria were 1) a Southwest Oncology Group performance status score 1 (ie, incapable of doing light housework or office work), 2) active liver or kidney disease, 3) prior diagnosis of cancer (excluding nonmelanoma skin cancer), 4) diagnosis of HIV infection, 5) on immunosuppressive therapy, 6) diminished mental capacity, and 7) taking ͧ50 g/d of selenium supplements in the previous 6 mo (by patient report).
Subjects with known thyroid disease (n ҃ 24) or who showed biochemical evidence of hypothyroidism or hyperthyroidism in the trial by having a baseline TSH measurement outside the reference range (0.15-3.5 mU/L) were excluded from the thyroid substudy (n ҃ 27). The reason for the latter restriction is because elevated TSH may indicate the presence of autoimmune thyroiditis, whereas lowered TSH may indicate overt or subclinical hyperthyroidism; both situations could result in changes in thyroid function tests with time and disease progression. In neither case is an abnormal TSH value amenable to alteration by selenium supplementation. Use of a euthyroid population therefore reduces noise in the data and gives a better chance of seeing any modification of the T 3 :T 4 resulting from selenium supplementation. The study had approval from the appropriate UK Local Research Ethics Committees, and participants provided written informed consent to participate.
Protocol
After a 4-wk placebo run-in, 501 volunteers were randomly assigned to 1 of 4 treatment regimes: placebo or 100, 200, or 300 g Se/d for a minimum of 6 mo. The intervention agent was high-selenium yeast, SelenoPrecise (Pharma Nord, Vejle, Denmark), or an identical placebo yeast. Central randomization was by computer-generated permuted blocks stratified by general practice, sex, and age group. Research nurses telephoned the independent randomization service at the Clinical Trials and Statistics Unit, Institute of Cancer Research, to obtain an anonymous code for each volunteer. Participants collected their corresponding prelabeled tablets from the research nurses.
Participants and general practice personnel were blinded to study treatment. Participants provided a blood sample at both baseline and 6 mo (when visiting the general practices for the purpose of the PRECISE pilot). Heparinized plasma was prepared and frozen at the practices. Plasma samples were transferred to the University of Surrey where they were stored at Ҁ80°C. All transfer of samples between centers was done on dry ice.
Questionnaires were used to collect demographic data and medical history at baseline and to ascertain use of medication and supplements at baseline and 6 mo. Compliance with randomized treatment was determined by pill count and by measuring each participant's plasma selenium and comparing it with the mean of the group. Reasons for participant withdrawal were noted.
Thyroid function assessment
Thyroid function was determined from the plasma samples from the baseline and 6-mo follow-up visits. Although strictly speaking free thyroid hormone should be measured, sample stability and analytic reliability of assays for total thyroid hormone are greater than those for free hormone (27, 28) . We therefore chose to assess thyroid function by measuring all of the following in each plasma sample: total T 4 , total T 3 , free T 4 , free T 3 , and TSH.
Thyroid analyses were performed at the University Department of Clinical Biochemistry, Edinburgh Royal Infirmary, with the use of an enhanced chemiluminescence automated immunoassay system (Vitros ECi; Ortho Clinical Diagnostics, Amersham, United Kingdom) (29) . This system uses a thirdgeneration assay for TSH (functional sensitivity 0.02 mU/L). Furthermore, labeled antibody methods for free thyroid hormone measurements have been shown to correlate well with equilibrium dialysis values in a range of clinical conditions (30) . Over the concentration ranges measured in the study, the within-and between-run CV for these assays were all 5%.
Selenium measurement
Lithium-heparin plasma was measured for selenium at the Central Science Laboratory, Sand Hutton, United Kingdom, by hydride-generation inductively coupled-plasma mass spectrometry. Weighed plasma samples were prepared by microwave digestion (Multiwave; Perkin-Elmer, Bucks, United Kingdom) and reduced to selenium (IV), before being made up to volume for analysis. All reagents were "Analar" grade (or better), and the water used was Millipore grade (18 M⍀). Quality control procedures were accredited under the UK Accreditation Scheme. Accuracy was assured by analysis of certified reference materials, namely, seronorm serum, mean value (10 determinations) 85.5 ng/g, RSD 12.7% (certified 86 ng/g); NIST 1598 bovine serum, mean value (16 determinations) 43.5 ng/g, RSD 6.2% (certified 42.4 Ȁ 3.5 ng/g). The limit of detection was 5 ng/g and the mean recovery was 108% (12 determinations). Plasma selenium measurements can be converted from ng/g to g/L by multiplying by 1.027, the density of plasma (31) .
Statistical analysis
TSH, free and total T 3 , and free and total T 4 were log 10 transformed to better approximate the normal distribution. The effect of selenium supplementation on markers of thyroid function was assessed by analysis of covariance with intervention dose included as a 4-level factor. Subsequent models were adjusted for baseline concentrations of the relevant thyroid marker, sex, age group, and clinic location. Baseline comparisons were made with 1-factor analysis of variance, with Fisher's least significant difference test used for post hoc comparisons as appropriate. The correlations between the various thyroid markers and selenium status at baseline were assessed with Pearson's product-moment correlation. The correlation between baseline and follow-up measurements in participants assigned to placebo was used to assess the extent of within-person variation in the markers measured. Withdrawals were analyzed with chi-square tests. Participants were excluded if they did not provide a blood sample at both time points, were taking thyroid medication, or had baseline TSH measurements outside the laboratory reference range of 0.15-3.5 mU/L. The remaining 368 participants were included regardless of their compliance with allocated treatment. Statistical analysis was performed with the use of SPSS version 11.5 for WINDOWS (SPSS Inc, Chicago, IL). Unless otherwise stated, data are expressed as mean (ȀSD). To account for multiple comparisons, P values of 0.01 are considered statistically significant throughout.
RESULTS

Participants
Participants (n ҃ 501) were recruited between June 2000 and July 2001. Of those participants, 34 withdrew from treatment and were unable to be evaluated in this analysis because they had no 6-mo blood sample, 39 were excluded because of thyroid problems, and a further 60 were missing at least one of the baseline or 6-mo follow-up laboratory measures (see Figure 1 for reasons) . Results for the remaining 368 participants with complete records are reported below.
Compliance with treatment
Of the 368 participants, 356 (97%) included in this analysis were compliant (missed 10% of the total number of tablets they should have taken) according to pill count. Nonprotocol use of over-the-counter selenium ("drop-ins") was assessed by inspection of the distribution of plasma selenium concentrations in the placebo group at 6 mo. Two (2.2%) of the 90 participants taking placebo had a selenium status 2 SDs above the mean, reasonably consistent with the 2.5% expected (being approximately normally distributed). We have made the assumption, therefore, that drop-ins were rare. One participant (of 368) reported using supplements that provided 25 g of selenium; because this was within the 50-g daily limit imposed by our exclusion criteria, this participant was included in the analysis.
Withdrawals
Thirty-four (7%) of the initial 501 participants withdrew from study treatment within the first 6 mo. No significant difference was observed in the numbers of participants withdrawing from treatment between groups (7 in the placebo group, 10 in the 100-g group, 5 in the 200-g group, and 12 in the 300-g group; chi-square test ҃ 3.5, df ҃ 3, P ҃ 0.31). Of those participants, 13 withdrew because of adverse events, 7 of which were abdominal or stomach problems. Other reasons for discontinuation appeared unrelated to treatment (Figure 1 ).
Selenium status
Overall mean plasma selenium at baseline was 88. . Selenium status did not differ significantly in the placebo group between baseline and 6 mo (mean difference: Ҁ2.5 ng/g; 95% CI: Ҁ5.7, 0.6 ng/g; P ҃ 0.11).
Baseline thyroid function
At baseline, free T 3 , free T 3 :T 4 , and total T 3 :T 4 were significantly higher in men than in women (all P ͨ 0.001), whereas total T 4 was lower (P 0.001; Table 1 ). Free T 4 was higher in the oldest age group than in the younger 2 age groups (P ҃ 0.001) with a corresponding tendency toward a lower free T 3 :T 4 (P ͨ 0.05). No further evidence was observed of any other age-or sex-related difference in the baseline thyroid function.
Free T 4 correlated negatively with baseline selenium status (r ҃ Ҁ0.19, P 0.001), with this association also reflected in the free T 3 :T 4 , which showed a marginal positive correlation with selenium status (r ҃ 0.12, P ҃ 0.02). None of the other measured markers was significantly associated with baseline selenium status.
Within-person variability
The extent of within-person variability for selenium concentration and the markers of thyroid function were assessed by correlating baseline and 6-mo values in the 90 participants assigned to the placebo group. Scatterplots (Figure 3) show the correlations obtained. Total T 4 , TSH, and free T 4 were the most stable during the 6-mo time period, although all measured variables exhibited moderate-to-strong repeatability during this period. This would suggest that the total T 3 :T 4 and free T 3 :T 4 represent suitable markers for detecting any increase in T 4 to T 3 conversion that might result from selenium supplementation.
Effect of treatment
Concentrations of TSH, free and total T 4 , free and total T 3 , as well as free T 3 :T 4 and total T 3 :T 4 , at baseline and after 6 mo for the 4 treatment groups are shown in Table 2 . At baseline, no evidence was observed of any significant differences in these values between the 4 randomized treatment groups (P 0.18 for 1 Baseline comparisons were made on log 10 -transformed data; however, marker values are presented here on natural scale for ease of interpretation. TSH, thyroid-stimulating hormone; TT 4 , total thyroxine; TT 3 , total 3,3Ј, 5-triiodothyronine; FT 4 , free T 4 ; FT 3 , free T 3 .
2 x Ȁ SD (all such values). 3 P 0.001; assessed by one-factor ANOVA (plus Fisher's least significant difference test for age group post hoc comparisons compared with the youngest age group). 4 Pearson's correlation with baseline selenium concentration.
all markers). Furthermore, no evidence was observed of an effect of selenium intervention on any of the measured markers of thyroid function at 6 mo, either unadjusted or after adjustment for baseline values of the relevant thyroid marker, participant sex, age group, and clinic location ( Table 2 ). In particular, no evidence was observed of an effect of selenium supplementation on the free T 3 :T 4 or total T 3 :T 4 .
DISCUSSION
The effect of selenium supplementation on thyroid function was investigated previously in a number of studies of which our randomized trial is the largest: 368 subjects as opposed to 160, 172, and 60 (32, 33) ; 60 (23); 52 (34); 52 (35); 36 (6); and 11 (36) subjects. The duration of treatment in our study was also somewhat greater: 26 wk as opposed to 20, 14, 13, 9, and 4 wk.
We found no effect of daily supplementation with 100, 200, or 300 g of selenium on thyroid function, as measured by TSH, total or free T 4 , total or free T 3 , total T 4 :T 3 , or free T 4 :T 3 , despite significant increases in plasma selenium. This is in contrast to the findings of supplementation studies in subjects of low or relatively low selenium status that found a reduction in serum or plasma T 4 (6, 34, 35) . For instance, in subjects from Otago, New (35) . In contrast to those findings, 2 later New Zealand supplementation studies in volunteers of somewhat higher selenium status (77 and 85 g/L) showed only a nonsignificant trend toward a decrease in total T 4 (32, 33) , in line with our results.
Mean baseline plasma selenium in our study (89 ng/g, equivalent to 91 g/L) was considerably higher than in intervention studies that found a beneficial effect of selenium supplementation on thyroid function, as represented by a significant change in total or free T 4 (6, 34, 35) or a significant correlation between plasma selenium and the total T 3 :T 4 (23) . Thus, initial selenium status of our participants was arguably in the replete range where most selenoproteins should show maximal activity (35, 37, 38) . Because animal studies have shown that thyroid function is successfully maintained over 6 generations of selenium deficiency and that iodothyronine deiodinase activity is preferentially preserved, ranking high in the hierarchy of selenium supply to selenoproteins, it is unlikely that the baseline activity of the iodothyronine deiodinases was limited by selenium status in most of our participants (38 -40) .
Although we saw no effects of supplementation, we did find a number of differences at baseline. With regard to sex wherein differences have previously been reported (41-43), we found significantly lower total T 4 and significantly higher free T 3 in men than in women, resulting in men having higher free T 3 :T 4 and total T 3 :T 4 . We saw some effect of age on thyroid function; free T 4 was higher in the oldest age group (P ҃ 0.001) and the free T 3 :T 4 tended to be correspondingly lower (P ͨ 0.05), paralleling the results reported by Olivieri et al (6, 44) on T 4 and T 3 :T 4 . Furthermore, baseline selenium status correlated negatively with free T 4 and marginally positively with free T 3 :T 4 , suggesting a potential benefit of higher selenium status in this population. However, the relation was not strong, with selenium status accounting for only 3.6% and 1.4%, respectively, of the variation seen, suggesting that, at least within the baseline status range pertaining in this population group, selenium status is not an important factor in determining thyroid function.
In fact, mean baseline selenium status in our participants, at 89 ng/g (equivalent to 91 g/L), was considerably higher than the mean value of 79 g/L measured in free-living subjects aged 65-74 y from 80 areas of England, Scotland, and Wales (25) . This is perhaps not too surprising because our participants were somewhat younger (60 -74 y compared with 65-74 y) and were healthy volunteers, a quarter of whom came from East Anglia where selenium status is relatively high (25, 45) . It is likely that Thomson (46) , is adequate for optimal iodothyronine deiodinase activity. Although our highest selenium dose (300 g) was similar to the amount of selenium supplied in the high-selenium diet fed to 5 male volunteers by Hawkes and Keim (36), we did not see the decrease in serum total T 3 or significant increase in serum TSH that they described, which they attributed to subclinical hypothyroidism induced by this selenium dose. Given that they achieved this high selenium intake by dietary means alone, varying in particular sources of beef and rice (47) , it is possible that other components of the diet (eg, iodine, iron, zinc, copper, manganese, or goitrogens) were responsible for the changes that they saw (48 -50) , as they have acknowledged (47) .
In conclusion, we found no evidence of an effect of selenium supplementation on thyroid function in a subset of 368 apparently euthyroid, elderly, UK volunteers of moderate selenium status, participating in a randomized, double-blind, placebocontrolled trial. In particular, no effect was observed on the conversion of T 4 to T 3 as evidenced by the free T 4 :T 3 or total T 4 :T 3 , a finding consonant with the weakness of the baseline correlations found with selenium status. Although this suggests that selenium intake is adequate for thyroid function in the UK regions where our study was conducted, this might not be the case for elderly persons living in areas of lower selenium intake (17, 23, 51) nor for those with autoimmune thyroiditis for whom additional selenium may be of benefit (14 -16). Our study is, however, reassuring in that no adverse effects of selenium on thyroid metabolism were seen up to a total intake (food plus supplement) of Ȃ350 g/d.
